Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK delivers strong 2023 performance and upgrades growth outlooks
FY 2023 performance highlights
Download (PDF - 942.2KB)GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.
Download (PDF - 167.1KB)European Commission authorises GSK’s Omjjara (momelotinib)
First medicine in the EU specifically indicated for splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Download (PDF - 152.5KB)Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype
Mepolizumab is the first targeted IL-5 biologic available in China as an add-on maintenance treatment for severe eosinophilic asthma.
Download (PDF - 260.3KB)GSK enters agreement to acquire Aiolos Bio
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody.
Download (PDF - 235.3KB)GSK enters exclusive license agreement with Hansoh for HS-20093
Hansoh’s HS-20093 builds on GSK’s oncology portfolio of clinical-stage antibody-drug conjugates.
Download (PDF - 182.9KB)Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial
Results reinforce development approach of using Jemperli as a backbone in immuno-oncology-based combination therapies
Download (PDF - 203.3KB)Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk
Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59.
Download (PDF - 249.3KB)GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer
European Commission converts previous conditional approval to full approval as monotherapy for second-line dMMR/MSI-H endometrial cancer.
Download (PDF - 195.8KB)New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions
Findings to be presented at the Global Coalition on Aging’s Silver Economy Forum 2023.
Download (PDF - 162.6KB)New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence
A new GSK survey shows a large number of adults do not understand how shingles may be triggered.
Download (PDF - 256.2KB)GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma
Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
Download (PDF - 227.8KB)GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials
Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler.
Download (PDF - 194.3KB)GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
Decision on EU marketing authorisation expected for momelotinib by early 2024.
Download (PDF - 206.5KB)Strong year-to-date and Q3 performance drives upgrade to full-year guidance
Q3 2023 performance highlights
Download (PDF - 804.7KB)GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
GSK plc and Arrowhead Pharmaceuticals Inc. today announced that they have reached an agreement with Janssen Pharmaceuticals, Inc.
Download (PDF - 234.7KB)Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer
Statistically significant and clinically meaningful overall survival benefit observed in the overall population in the trial.
Download (PDF - 503.6KB)GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK
GSK to invest £6m in STEM equity-focused initiatives in the UK over ten years to tackle barriers to entry in STEM careers.
Download (PDF - 208.2KB)ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment
The complete long-acting regimen enables virologically suppressed people living with HIV in China to reduce treatment dosing days.
Download (PDF - 217.9KB)New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease
Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59.
Download (PDF - 245.6KB)